Conquering Diseases

Study Of An Experimental Drug Combination To Prevent Cancer Recurrence For People With Bladder Cancer

Description

Seeking men and women whose high-risk, non-muscle invasive bladder cancer has not spread to the muscle for a study comparing the standard Bacillus Calmette-Guerin (BCG) immunotherapy to an investigational chemotherapy drug combination.

Overview

Participants will be randomly assigned to get either the standard Bacillus Calmette-Guerin (BCG) immunotherapy or an experimental chemotherapy combination given through a catheter directly into the bladder. People receiving BCG immunotherapy who show a response will continue to be treated with BCG once a week for three weeks in a row for up to 3 years. People receiving the experimental chemotherapy who show a response will continue to get the chemotherapy monthly for up to 2 years.

What we're hoping for

We are comparing an experimental chemotherapy to the standard Bacillus Calmette-Guerin (BCG) immunotherapy for prevention of the return of cancer in people with high-risk, non-muscle invasive bladder cancer has not spread to the muscle

Additional Information

ClinicalTrials.gov Identifier: NCT05538663

 Principal Investigator

Jennifer  Yates, MD

UMass Memorial Health

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989